Cite

    Peter Gross et al.. “Con: Tolvaptan for autosomal dominant polycystic kidney disease—do we know all the answers?.” Nephrology dialysis transplantation, vol. 34, no. 1, 2019, pp. 35–37. http://access.bl.uk/ark:/81055/vdc_100092359653.0x000023